Kaiyan Chen

No. 1 Banshan East Road
Hangzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody-Drug conjugates.

Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody-Drug conjugates.

Journal: Cancer treatment reviews

Published: October 03, 2025

SH3BGRL2 as a vital tumor suppressor and prognostic factor in human esophageal squamous cell carcinoma.

SH3BGRL2 as a vital tumor suppressor and prognostic factor in human esophageal squamous cell carcinoma.

Journal: Journal of thoracic disease

Published: September 12, 2025

High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical Trial.

High-Dose Aumolertinib for Untreated EGFR-Variant Non-Small Cell Lung Cancer With Brain Metastases: The ACHIEVE Phase 2 Nonrandomized Clinical Trial.

Journal: JAMA oncology

Published: June 26, 2025

Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive-stage small-cell lung cancer: Results of two prospective phase II studies.

Tislelizumab plus sitravatinib or anlotinib as maintenance therapy in extensive-stage small-cell lung cancer: Results of two prospective phase II studies.

Journal: International journal of cancer

Published: March 12, 2025

Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis.

Efficacy and safety of first-line PD-1/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis.

Journal: Therapeutic advances in medical oncology

Published: December 11, 2024

Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases.

Survival and prognostic factors of HER2-mutant advanced non-small cell lung cancer with brain metastases.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: October 22, 2024

Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial.

Brain radiotherapy combined with camrelizumab and platinum-doublet chemotherapy for previously untreated advanced non-small-cell lung cancer with brain metastases (C-Brain): a multicentre, single-arm, phase 2 trial.

Journal: The Lancet. Oncology

Published: July 11, 2024

Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives.

Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives.

Journal: International journal of cancer

Published: December 04, 2023

Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.

Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 22, 2023

A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.

A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.

Journal: Frontiers in immunology

Published: July 14, 2023

Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial.

Sintilimab plus anlotinib as second- or third-line therapy in metastatic non-small cell lung cancer with uncommon epidermal growth factor receptor mutations: A prospective, single-arm, phase II trial.

Journal: Cancer medicine

Published: May 20, 2023

Complete response of a locally advanced pulmonary hepatoid adenocarcinoma patient to perioperative XELOX-containing chemoimmunotherapy.

Complete response of a locally advanced pulmonary hepatoid adenocarcinoma patient to perioperative XELOX-containing chemoimmunotherapy.

Journal: Genes & diseases

Published: August 13, 2022

Showing 1-12 of 41

Last Updated: 09/26/2026